Using rTMS to treat dyskinesia caused by Parkinson's medication
Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
This study is testing if a new brain stimulation technique can help people with Parkinson's who experience movement problems from their medication feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 68 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Danish Research Centre for Magnetic Resonance Academic / other |
| Locations | 1 site (Hvidovre) |
| Trial ID | NCT06570824 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in treating levodopa-induced dyskinesia (LID) in patients with Parkinson's Disease. It focuses on delivering patterned stimulation to the pre-supplementary motor area to delay the onset of LID and reduce its severity. The study aims to optimize stimulation parameters based on individual neuroanatomy and explore the impact of high-frequency bursts of rTMS. By targeting specific brain regions, the research seeks to provide insights into the mechanisms of LID and improve treatment outcomes for affected patients.
Who should consider this trial
Good fit: Ideal candidates are individuals with clinically established Parkinson's Disease experiencing peak-of-dose levodopa-induced dyskinesia.
Not a fit: Patients with psychiatric disorders, a history of epilepsy, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from dyskinesia related to Parkinson's medication.
How similar studies have performed: Previous studies have shown promising results with rTMS targeting the pre-supplementary motor area, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically established or probable PD * Clinical Diagnostic Criteria for Parkinson's Disease * Peak-of-dose levodopa-induced dyskinesia. * Stable antiparkinsonian medicine for at least four weeks. * Signed informed consent. Exclusion Criteria: * Psychiatric disorders. * Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin). * Regular usage of benzodiazepines and opioids (more than once per week). * History of neurological disease other than Parkinson's disease. * History of epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Contraindications for MRI scan * Female participants of childbearing age must not be pregnant and that they must use contraception during the trial. * Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.
Where this trial is running
Hvidovre
- Drcmr — Hvidovre, Denmark (Recruiting)
Study contacts
- Principal investigator: Hartwig R. Siebner, Prof. — Head of Research, Prof, DMSc
- Study coordinator: Laura Sakalauskaite, MD
- Email: laura.sakalauskaite.01@regionh.dk
- Phone: +45 38621184
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.